We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanobone Material Activates Natural Repair Signals to Regrow Bone

By HospiMedica International staff writers
Posted on 04 Sep 2026

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. More...

Repairing the resulting jawbone gap often requires invasive bone grafting at 10 to 12 years of age, with lasting effects on speech and self-confidence. Surgeons have had few alternatives for decades. To help address this challenge, University of Sydney researchers have developed a biodegradable “nanobone” material intended to prompt the body to regrow bone.

The biodegradable nanobone is a calcium‑aluminosilicate nanomaterial created at the University of Sydney’s School of Dentistry with contributions from the Charles Perkins Centre and Sydney Nano, in collaboration with the University of Queensland. The study was published in ACS Nano in 2026. The approach aims to provide a future alternative to grafts that have changed little in more than 50 years and often require harvesting autologous bone.

The material is designed to teach the body to heal itself. Instead of supplying manufactured growth factors, it activates latent transforming growth factor beta 1 (TGF‑β1) that is already present in tissue. This activation recruits bone‑forming stem cells to the defect and supports their maturation into bone‑producing cells. The nanomaterial also promotes rapid blood clotting in about 30 seconds, which helps stabilize the site in the earliest phase of repair.

In a preclinical bone model, the nanobone generated approximately 80 percent more new bone than a material control after eight weeks. It also increased activation of a key bone‑repair growth factor to about 10 times the level achieved with conventional methods. The authors note that more than four million bone repair procedures are performed globally each year, underscoring the scale of the clinical need.

According to the investigators, this is the first demonstration of a single nanomaterial platform that combines rapid hemostasis, activation of endogenous growth signals, stem‑cell recruitment, and enhanced bone regeneration. While further testing is required before human trials, potential applications could extend beyond cleft lip and palate to traumatic injuries, tooth loss, and other difficult‑to‑repair defects. The team is also exploring integration with personalized three‑dimensional printed scaffolds tailored to individual patient anatomy.

“The material activates dormant repair signals in the body, triggering a cascade of healing processes that attract bone-forming stem cells and stimulate new bone growth,” said Associate Professor Chun Xu, Sydney Horizon Fellow in the Faculty of Medicine and Health.

“Every patient is different and every bone defect is different. In the future, we hope to combine these materials with advanced 3D-printing technologies so treatments can be tailored to the specific needs of each patient,” added Prof. Xu.

Related Links
University of Sydney’s School of Dentistry
 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Tourniquet System
heidi– mein Tourniquet
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.